Download PDF
Thromb Haemost 2013; 110(04): 626-627
DOI: 10.1160/TH13-05-0407
T&H Images
Schattauer GmbH

Successful treatment of acute portal vein thrombosis with rivaroxaban

Sven Pannach
1   Division Gastroenterology, Medical Clinic I, Dresden University Hospital “Carl Gustav Carus”, Dresden, Germany
,
Jana Babatz
1   Division Gastroenterology, Medical Clinic I, Dresden University Hospital “Carl Gustav Carus”, Dresden, Germany
,
Jan Beyer-Westendorf
2   Center for Vascular Diseases and Medical Clinic III, Dresden University Hospital “Carl Gustav Carus”, Dresden, Germany
› Author Affiliations
Further Information

Publication History

Received: 21 May 2013

Accepted after minor revision: 10 June 2013

Publication Date:
01 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Thatipelli MR, McBane RD, Hodge DO. et al. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol 2010; 8: 200-205.
    CrossrefPubMedGoogle Scholar
  • 2 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e419S-e94S.
    CrossrefPubMedGoogle Scholar
  • 3 Riva N, Donadini MP, Dentali F. et al. Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res 2012; 130 (Suppl. 01) S1-S3.
    CrossrefPubMedGoogle Scholar
  • 4 Turpie AG, Kreutz R, Llau J. et al. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108: 876-886.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Hammerstingl C, Potzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost 2013; 109: 583-584.
    Article in Thieme ConnectPubMedGoogle Scholar